2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

被引：37

作者：

Losa, F. ^{[1
]}

Iglesias, L. ^{[2
]}

Pane, M. ^{[3
]}

Sanz, J. ^{[4
]}

Nieto, B. ^{[5
]}

Fuste, V. ^{[6
]}

de la Cruz-Merino, L. ^{[7
]}

Concha, A. ^{[8
]}

Balana, C. ^{[9
]}

Matias-Guiu, X. ^{[10
,11
]}

机构：

[1] Hosp St Joan Despi, Med Oncol Dept, Inst Catala Oncol, ICO Hosp, Carrer Jacint Verdaguer 90, Barcelona 08970, Spain

[2] Hosp Univ Doce Octubre, Med Oncol Dept, Madrid, Spain

[3] Hosp Univ Bellvitge, Pathol Dept, Barcelona, Spain

[4] Hosp Clin San Carlos, Pathol Dept, Madrid, Spain

[5] Hosp Univ Leon, Med Oncol Dept, Leon, Spain

[6] Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain

[7] Hosp Univ Virgen Macarena, Med Oncol Dept, Seville, Spain

[8] Hosp Univ A Coruna, Pathol Dept, La Coruna, Spain

[9] Inst Catala Oncol, Med Oncol Dept, Barcelona, Spain

[10] Hosp Univ Arnau de Vilanova Lleida, Pathol Dept, Barcelona, Spain

[11] Hosp Univ Bellvitge, IRBLLEIDA, IDIBELL, CIBERONC, Barcelona, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 11期

关键词：

Cancer of unknown primary; Diagnosis; Immunohistochemistry; Biopsy; Prognosis; Chemotherapy; Molecular pathology; Histopathology; PANCREATIC NEUROENDOCRINE TUMORS; PRIMARY SITE; PRIMARY CUP; PRIMARY ORIGIN; THERAPEUTIC MANAGEMENT; METASTATIC TUMORS; CARCINOMA; EXPRESSION; SURVIVAL; TISSUE;

D O I：

10.1007/s12094-018-1899-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer of unknown primary (CUP) is defined as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They differ from other primary tumours in their biological features and how they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. Depending on the type of study done, CUP can account for 2-9% of all cancer patients, mostly 60-75years old. This article reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP. The main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed.

引用

页码：1361 / 1372

页数：12

共 71 条

[1] Gene expression microarray-based assay to determine tumor site of origin in a series of metastatic tumors to the ovary and peritoneal carcinomatosis of suspected gynecologic origin [J].

Azueta, Ainara ;

Maiques, Oscar ;

Velasco, Ana ;

Santacana, Maria ;

Pallares, Judith ;

Novell, Anna ;

Llombart-Cussac, Antonio ;

Gonzalez-Tallada, Xavier ;

Mozos, Ana ;

Prat, Jaime ;

Pillai, Raji ;

Mata, Manuel ;

Matias-Guiu, Xavier .

HUMAN PATHOLOGY, 2013, 44 (01) :20-28

[2] Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961-2010 [J].

Brewster, David H. ;

Lang, Jaroslaw ;

Bhatti, Lesley A. ;

Thomson, Catherine S. ;

Oien, Karin A. .

CANCER EPIDEMIOLOGY, 2014, 38 (03) :227-234

[3] Clinical guideline SEOM: cancer of unknown primary site [J].

Collado Martin, R. ;

Garcia Palomo, A. ;

de la Cruz Merino, L. ;

Borrega Garcia, P. ;

Baron Duarte, F. J. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (12) :1091-1097

[4] Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site:: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) [J].

Culine, S ;

Lortholary, A ;

Voigt, JJ ;

Bugat, R ;

Théodore, C ;

Priou, F ;

Kaminsky, MC ;

Lesimple, T ;

Pivot, X ;

Coudert, B ;

Douillar, JY ;

Merrouche, Y ;

Allouache, J ;

Goupil, A ;

Négrier, S ;

Viala, J ;

Petrow, P ;

Bouzy, J ;

Laplanche, A ;

Fizazi, K .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3479-3482

[5] Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site [J].

Culine, S ;

Kramar, A ;

Saghatchian, M ;

Bugat, R ;

Lesimple, T ;

Lortholary, A ;

Merrouche, Y ;

Laplanche, A ;

Fizazi, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4679-4683

[6]

Delgado-Bolton RC, 2003, J NUCL MED, V44, P1301

[7] Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers [J].

Dumur, Catherine I. ;

Lyons-Weiler, Maureen ;

Sciulli, Christin ;

Garrett, Carleton T. ;

Schrijver, Iris ;

Holley, Tara K. ;

Rodriguez-Paris, Juan ;

Pollack, Jonathan R. ;

Zehnder, James L. ;

Price, Melissa ;

Hagenkord, Jill M. ;

Rigl, C. Ted ;

Buturovic, Ljubomir J. ;

Anderson, Glenda G. ;

Monzon, Federico A. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (01) :67-77

[8] Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer [J].

Economopoulou, Panagiota ;

Mountzios, Giannis ;

Pavlidis, Nicholas ;

Pentheroudakis, George .

CANCER TREATMENT REVIEWS, 2015, 41 (07) :598-604

[9] Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification [J].

Erlander, Mark G. ;

Ma, Xiao-Jun ;

Kesty, Nicole C. ;

Bao, Lei ;

Salunga, Ranelle ;

Schnabel, Catherine A. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2011, 13 (05) :493-503

[10]

Fehri Rania, 2013, Tunis Med, V91, P205

← 1 2 3 4 5 6 7 8 →